{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Arai H"],"funding":["Gloria Borges Wunderglo Foundation","Dhont Family Foundation","National Cancer Institute","NCI NIH HHS"],"pagination":["113914"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11323978"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["201"],"pubmed_abstract":["Background
CDC37 is a key determinant of client kinase recruitment to the HSP90 chaperoning system. We hypothesized that kinase-specific dependency on CDC37 alters the efficacy of targeted therapies for metastatic colorectal cancer (mCRC).Material and methods
Two independent mCRC cohorts were analyzed to compare the survival outcomes between CDC37-high and CDC37-low patients (stratified by the median cutoff values): the CALGB/SWOG 80405 trial (226 and 207 patients receiving first-line bevacizumab- and cetuximab-containing chemotherapies, respectively) and Japanese retrospective (50 refractory patients receiving regorafenib) cohorts. A dataset of specimens submitted to a commercial CLIA-certified laboratory was utilized to characterize molecular profiles of CDC37-high (top q"],"journal":["European journal of cancer (Oxford, England : 1990)"],"pubmed_title":["Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer."],"pmcid":["PMC11323978"],"funding_grant_id":["U10 CA180882","P30 CA014089","UG1 CA239758","UG1 CA180830","UG1 CA233163","U10 CA180821","U10 CA180888","UG1 CA233373"],"pubmed_authors":["Kubota Y","Weinberg BA","Michael Korn W","Izawa N","Doi A","Wang J","Millstein J","Goel S","Baca Y","Innocenti F","Soni S","Venook AP","Denda T","Marshall J","Horie Y","Algaze S","Lenz HJ","Battaglin F","Scott AJ","Xiu J","Goldberg RM","Hwang JJ","Ou FS","Hall MJ","Jayachandran P","Zhang W","Yang Y","Umemoto K","Lou E","Sunakawa Y","Arai H","Takeda H"],"additional_accession":[]},"is_claimable":false,"name":"Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer.","description":"Background
CDC37 is a key determinant of client kinase recruitment to the HSP90 chaperoning system. We hypothesized that kinase-specific dependency on CDC37 alters the efficacy of targeted therapies for metastatic colorectal cancer (mCRC).Material and methods
Two independent mCRC cohorts were analyzed to compare the survival outcomes between CDC37-high and CDC37-low patients (stratified by the median cutoff values): the CALGB/SWOG 80405 trial (226 and 207 patients receiving first-line bevacizumab- and cetuximab-containing chemotherapies, respectively) and Japanese retrospective (50 refractory patients receiving regorafenib) cohorts. A dataset of specimens submitted to a commercial CLIA-certified laboratory was utilized to characterize molecular profiles of CDC37-high (top q","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-06-01T05:48:15.085Z","creation":"2026-04-08T09:36:22.572Z"},"accession":"S-EPMC11323978","cross_references":{"pubmed":["38359495"],"doi":["10.1016/j.ejca.2024.113914"]}}